Top

Diabetology International

Published in:

12-01-2024 | Polyneuropathy | Report of the Committee

Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10)

Authors: Hideki Kamiya, Tatsuhito Himeno, Atsuko Watarai, Masayuki Baba, Rimei Nishimura, Naoko Tajima, Jiro Nakamura

Published in: Diabetology International | Issue 1/2024

Abstract

Aim/introduction

This study aims to investigate the prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy (DSPN) in patients with type 2 diabetes registered in the Japan Diabetes Complication and its Prevention Prospective (JDCP) study.

Materials and methods

In the study, 6338 patients with diabetes who had been treated by diabetes specialists were registered in 2007–2009. Of these, patients with type 2 diabetes who could be evaluated for DSPN were analyzed using t test, chi-square test, and logistic regression analyses. DSPN was diagnosed using the Simple Diagnostic Criteria for Diabetic Polyneuropathy proposed by the Diabetic Neuropathy Study Group in Japan.

Results

Of the total participants, 5451 patients (mean age 61.4 years old and duration of diabetes 10.8 years) were analyzed. Based on the criteria, 35.8% of patients were diagnosed with DSPN. The prevalence of sensory symptoms was 25.8%. The following factors increased risk for DSPN: age [odds ratio (OR) 1.57, 95% confidence intervals (CI) 1.42–1.73], duration of diabetes (OR 1.32, 95% CI 1.21–1.43), body mass index (OR 1.19, 95% CI 1.09–1.30), systolic blood pressure (OR 1.06, 95% CI 1.01–1.10), hemoglobin A1c (OR 1.15, 95% CI 1.09–1.22), biguanides (OR 1.22, 95% CI 1.06–1.39), and insulin therapy (OR 1.59, 95% CI 1.36–1.84). The following factors decreased risk for DSPN: total cholesterol (OR 0.98, 95% CI 0.96–1.00) and exercise therapy (OR 0.85, 95% CI 0.73–0.98).

Conclusions

The baseline survey clarified the prevalence and characteristics of DSPN in Japanese patients with type 2 diabetes. The survey also revealed the risk factors of DSPN.

Available only for authorised users

Sasaki H, Kawamura N, Dyck P, Dyck P, Kihara M, Low P. Spectrum of diabetic neuropathies. Diabetol Int. 2020;11(2):87–96. https://doi.org/10.1007/s13340-019-00424-7.CrossRefPubMedPubMedCentral

Sugimoto K, Sozu T, Hoshino T, Watanabe Y, Tamura A, Yamazaki T, et al. Longitudinal effects of one-leg standing time on neuropathy outcomes in association with glycemic control in non-elderly patients with type 2 diabetes. J Diabetes Investig. 2022. https://doi.org/10.1111/jdi.13751. (Online ahead of print).CrossRefPubMedPubMedCentral

Hotta N, Kawamori R, Fukuda M, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med. 2012;29(12):1529–33. https://doi.org/10.1111/j.1464-5491.2012.03684.x.CrossRefPubMedPubMedCentral

Ziegler D, Papanas N, Schnell O, Nguyen BDT, Nguyen KT, Kulkantrakorn K, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12(4):464–75. https://doi.org/10.1111/jdi.13401.CrossRefPubMed

Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/nejm199309303291401.CrossRefPubMed

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–17.CrossRefPubMed

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. https://doi.org/10.1016/s0140-6736(10)60576-4.CrossRefPubMedPubMedCentral

Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281–9.CrossRefPubMed

Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999;41(Suppl 1):8–13. https://doi.org/10.1159/000052074.CrossRefPubMed

10.

Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93. https://doi.org/10.2337/dc10-1303.CrossRefPubMedPubMedCentral

11.

Yasuda H, Sanada M, Kitada K, Terashima T, Kim H, Sakaue Y, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract. 2007;77(Suppl 1):S178–83. https://doi.org/10.1016/j.diabres.2007.01.053.CrossRefPubMed

12.

Himeno T, Kamiya H, Nakamura J. Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions. J Diabetes Investig. 2020;11(1):5–16. https://doi.org/10.1111/jdi.13173.CrossRefPubMed

13.

Nishimura R, Izumi K, Hayashino Y, Origasa H, Noda M, Ueki K, et al. A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes-JDCP study 2. Diabetol Int. 2016;7(1):4–11. https://doi.org/10.1007/s13340-015-0248-5.CrossRefPubMedPubMedCentral

14.

Shikata K, Kodera R, Utsunomiya K, Koya D, Nishimura R, Miyamoto S, et al. Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: the Japan Diabetes Complication and its Prevention prospective study 5. J Diabetes Investig. 2020;11(2):325–32. https://doi.org/10.1111/jdi.13116.CrossRefPubMed

15.

Inagaki K, Kikuchi T, Noguchi T, Mitani A, Naruse K, Matsubara T, et al. A large-scale observational study to investigate the current status of diabetic complications and their prevention in Japan (JDCP study 6): baseline dental and oral findings. Diabetol Int. 2020;12(1):52–61. https://doi.org/10.1007/s13340-020-00465-3.CrossRefPubMedPubMedCentral

16.

Ponirakis G, Elhadd T, Chinnaiyan S, Hamza A, Sheik S, Kalathingal M, et al. Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar. J Diabetes Investig. 2021;12(4):592–600. https://doi.org/10.1111/jdi.13388.CrossRefPubMed

17.

Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(2):89–94. https://doi.org/10.1056/nejm199507133330203.CrossRefPubMed

18.

Kamiya H, Shibata Y, Himeno T, Tani H, Nakayama T, Murotani K, et al. Point-of-care nerve conduction device predicts the severity of diabetic polyneuropathy: a quantitative, but easy-to-use, prediction model. J Diabetes Investig. 2021;12(4):583–91. https://doi.org/10.1111/jdi.13386.CrossRefPubMed

19.

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377–84.CrossRefPubMed

20.

Lewis E, Lovblom L, Lanctot S, Scarr D, Cardinez N, Boulet G, et al. The association between physical activity time and neuropathy in longstanding type 1 diabetes: a cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. J Diabetes Complicat. 2022;36(3): 108134. https://doi.org/10.1016/j.jdiacomp.2022.108134.CrossRef

21.

Kluding P, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complicat. 2012;26(5):424–9. https://doi.org/10.1016/j.jdiacomp.2012.05.007.CrossRef

22.

Singleton JR, Marcus RL, Jackson JE, Lessard MK, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014;1(10):844–9. https://doi.org/10.1002/acn3.125.CrossRefPubMedPubMedCentral

23.

Cobianchi S, Arbat-Plana A, Lopez-Alvarez V, Navarro X. Neuroprotective effects of exercise treatments after injury: the dual role of neurotrophic factors. Curr Neuropharmacol. 2017;15(4):495–518. https://doi.org/10.2174/1570159X14666160330105132.CrossRefPubMedPubMedCentral

24.

Funakoshi H, Belluardo N, Arenas E, Yamamoto Y, Casabona A, Persson H, et al. Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science. 1995;268(5216):1495–9. https://doi.org/10.1126/science.7770776.CrossRefPubMed

25.

Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021;12(7):916–31. https://doi.org/10.4239/wjd.v12.i7.916.CrossRefPubMedPubMedCentral

26.

de Groot-Kamphuis D, van Dijk P, Groenier K, Houweling S, Bilo H, Kleefstra N. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med. 2013;71(7):386–90.PubMed

27.

Singh A, Kumar A, Karmakar D, Jha R. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med. 2013;59(4):253–7. https://doi.org/10.4103/0022-3859.123143.CrossRefPubMed

28.

Russo G, Giandalia A, Romeo E, Scarcella C, Gambadoro N, Zingale R, et al. Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. J Endocrinol Invest. 2016;39(3):305–14. https://doi.org/10.1007/s40618-015-0365-9.CrossRefPubMed

29.

Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B 12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019;11(9):729–43. https://doi.org/10.1111/1753-0407.12900.CrossRefPubMed

30.

Kamiya H, Himeno T, Watarai A, Baba M, Nishimura R, Tajima N, et al. Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10). J Jpn Diabetes Soc. 2023;66(8):645–54. https://doi.org/10.11213/tonyobyo.66.645.CrossRef

Title: Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10)
Authors: Hideki Kamiya
Tatsuhito Himeno
Atsuko Watarai
Masayuki Baba
Rimei Nishimura
Naoko Tajima
Jiro Nakamura
Publication date: 12-01-2024
Publisher: Springer Nature Singapore
Keywords: Polyneuropathy
Exercise Therapy
Exercise Therapy
Insulins
Insulins
Type 2 Diabetes
Biguanide
Published in: Diabetology International / Issue 1/2024
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-023-00678-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aim/introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

The Japanese version of Problem Areas in Diabetes Scale: a clinical and research tool to assess emotional functioning among people with diabetes

Adipose Tissue Plasticity and Insulin Signaling in the Pathogenesis of Type 2 Diabetes

Life-threatening coronary vasospasm in patients with type 2 diabetes treated with SGLT2 inhibitors

Acknowledgement to the Reviewers

Delayed-onset type 1 diabetes after immune checkpoint inhibitor monotherapy

Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials